Tamoxifen Citrate (54965-24-1) video
Tamoxifen Citrate (54965-24-1) Description
Tamoxifen Citrate is the citrate salt of an antineoplastic nonsteroidal selective estrogen receptor modulator (SERM). Tamoxifen competitively inhibits the binding of estradiol to estrogen receptors, thereby preventing the receptor from binding to the estrogen-response element on DNA. The result is a reduction in DNA synthesis and cellular response to estrogen. In addition, tamoxifen up-regulates the production of transforming growth factor B (TGFb), a factor that inhibits tumor cell growth, and down-regulates insulin-like growth factor 1 (IGF-1), a factor that stimulates breast cancer cell growth. Tamoxifen also down-regulates protein kinase C (PKC) expression in a dose-dependant manner, inhibiting signal transduction and producing an antiproliferative effect in tumors such as malignant glioma and other cancers that overexpress PKC.
Tamoxifen citrate use to the treatment and prevention of estrogen receptor positive breast cancer. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the endometrium.
Tamoxifen Citrate (54965-24-1) Specifications
|Product Name||Tamoxifen Citrate|
|Chemical Name||Istubal; Tamoxifen,|
|Drug Class||selective estrogen receptor modulator (SERM)|
|Molecular Weight||563.647 g/mol|
|Monoisotopic Mass||563.252 g/mol|
|Melting Point||97 °C|
|Freezing Point||No data available|
|Biological Half-Life||The decline in tamoxifen plasma concentrations is biphasic with a terminal elimination half-life of approximately 5 to 7 days. The estimated half-life of N-desmethyl tamoxifen is 14 days.|
|Color||White or off-white powder|
|Solubility||water solubility 0.000167 mg/mL at 25 °C|
|Application||use to the treatment and prevention of estrogen receptor positive breast cancer.|